Korean J Obstet Gynecol.
2006 Feb;49(2):276-283.
Clinical impact of prophylactic HPV (Human papillomavirus) Vaccine
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, College of Medicine, Ewha Womans University, Seoul, Korea. onco@ewha.ac.kr
Abstract
- A safe, and affordable HPV vaccine to prevent cervical cancer must meet several programatic challenges. First, It should be multivalent because many types of oncogenic HPVs are known as the important causative factor for the development of cervical cancer. Second, the vaccine must offer long-lasting immunity for protection against HPV infection, preferably without booster injections. Third, a vaccine suitable for developing countries must minimize financial and logical demands on health care systems. The ideal prophylactic HPV vaccine would have low production costs, a long shelf life, and no need for a cold chain; it also would require only a sing dose and would be administered orally or via a nasal spray rather than by injection. According to the above challenges, the clinical impact of prophylactic HPV vaccines would be largely determined. Absolutely, HPV vaccine development holds great promise for reducing the impact of cervical cancer on the world's women.
